
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Dimopoulos, M. A., Beksac, M., Benboubker, L., Roddie, H., Allietta, N., Broer, E., Couturier, C., Mazier, M.-A., Angermund, R., Facon, T.Volume:
98
Langue:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2013.084376
Date:
August, 2013
Fichier:
PDF, 842 KB
english, 2013